Symbols

HLVX(Delisted)

HilleVax·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HLVX

Hillevax, Inc.

A biopharmaceutical company that developing novel vaccines for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection

Industry

Established Date

03/25/2020

Listing Date

04/29/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.hillevax.com

Security Type

Common stock

Office address

321 Harrison Avenue, Boston, Massachusetts 02118

Business

Introduction

HilleVax, Inc., was incorporated in Delaware on March 25, 2020. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company's initial project, HIL -214, is a virus-like particle (VLP) -based vaccine candidate for the prevention of moderate to severe acute gastroenteritis (AGE) caused by norovirus infection. The company plans to initiate a Phase 2b clinical trial in the second quarter of 2022 to evaluate the safety, immunogenicity and efficacy of HIL -214 in infants.

Company Financials

EPS

HLVX has released its 2025 Q2 earnings. EPS was reported at -0.23, versus the expected -0.29, beating expectations. The chart below visualizes how HLVX has performed over recent quarters, highlighting trends in earnings surprises.